The stock market is often driven by narratives. But occasionally, a small-cap company delivers numbers so strong that it forces the market to take notice. Cupid Ltd did exactly that—for one day.
On November 12, 2026, shares of Cupid Ltd—a manufacturer of male and female condoms, lubricants, and consumer healthcare products—surged 10% to hit an all-time high of ₹389 on the BSE, following Q2 FY27 results that showed profit more than doubling.
But on November 13, the stock fell over 5% at the open after hitting a fresh record high of ₹393, as early buyers rushed to book profits. The draft’s claim that the stock “surged 10% on November 13” is factually incorrect—the surge happened a day earlier, and the subsequent session brought selling pressure.
Here is the ground reality of what Cupid actually reported, and whether the business justifies the excitement.
The Q2 Reality: Profit More Than Doubled
Cupid’s Q2 FY27 results, released on November 10, were exceptional across almost every line:
Revenue from operations: ₹187.86 crore, up 122% year-on-year from ₹84.45 crore.
Total income: ₹208.97 crore, up 132% year-on-year.
Net profit: ₹56.22 crore, up 133% year-on-year from ₹24.13 crore.
EBITDA: ₹54.77 crore, with a margin of 29%.
For H1 FY27, net profit rose 156% to ₹100.37 crore, and revenue climbed 137% to ₹342.58 crore.
The draft’s figures—”revenue +22%, net profit +35%, EBITDA margin 26%”—bear no resemblance to the actual numbers. The real story is far stronger.
The Real Growth Driver: It’s Not Just Condoms Anymore
The draft describes Cupid as primarily a tender-based contract manufacturer for governments and NGOs. That was true historically. It is no longer the dominant reality.
The domestic consumer healthcare and FMCG business now drives the majority of revenue. In H1 FY27, domestic sales contributed ₹224.64 crore, or 67% of total revenue, up from 41% in FY26. Within that, the Consumer Healthcare and FMCG segment alone accounted for 49% of first-half sales.
The international B2B business—including institutional tenders and the South Africa national condom programme—contributed the remaining 33% of H1 revenue. It is still important, but it is no longer the primary growth engine.
Cupid is executing a deliberate pivot from a B2B tender player to a domestic consumer brand. Partnerships with V2 Retail and Style Baazar are central to that strategy. The Style Baazar tie-up alone is expected to generate approximately ₹200 crore in FY27 revenue, with potential to scale beyond ₹500 crore in the coming years.
The Guidance Raise: Management Is Confident
Alongside the results, Cupid significantly raised its FY27 guidance:
FY27 revenue: At least ₹880 crore (up from previous guidance of ₹600 crore).
FY27 net profit: ₹275 crore or more (up from ₹180 crore).
The company also outlined FY28 and FY29 targets: FY28 revenue of at least ₹1,305 crore with net profit of approximately ₹390 crore; FY29 revenue exceeding ₹1,950 crore with net profit around ₹605 crore.
Management expects H2 FY27 to be “significantly stronger than H1,” supported by the commissioning of its Palava manufacturing facility in Q3 and the ramp-up of retail partnerships.
The Risks: Still a Small-Cap, Still Volatile
1. The stock has already run up massively. Cupid shares were up more than 253% year-to-date as of November 13, and over 544% in the past year. The easy money has been made in the short term.
2. Execution risk on the FMCG pivot. The domestic consumer business is growing fast, but it requires brand-building, distribution, and retail execution—skills that are different from tender-based manufacturing. The V2 Retail and Style Baazar partnerships must deliver on their promised contributions.
3. Liquidity and volatility. The stock’s sharp reversal on November 13—from a record high to a 5% decline—illustrates how quickly sentiment can shift in a small-cap that has tripled in a year.
4. Tender business remains lumpy. The international B2B segment still depends on large institutional contracts. A lost tender or delayed programme can create revenue gaps.
BS Maurya Research Verdict
Cupid Ltd is no longer the niche tender-based condom manufacturer that the draft describes. It is a rapidly growing domestic consumer healthcare and FMCG business with a profitable international B2B arm. The Q2 results were genuinely outstanding—profit more than doubled, revenue more than doubled, and management raised guidance substantially.
But the stock’s 10% surge on November 12 and 5% decline on November 13 tell you everything about the risk. This is a high-momentum small-cap that has already delivered extraordinary returns. The business quality is real, but the entry point matters enormously.
For investors with a high risk appetite and a long time horizon, Cupid is a legitimate growth story. For anyone chasing the momentum after a 250% year-to-date rally, the margin of safety is thin.
FAQ
Q1: Why did Cupid shares surge on November 12?
The stock jumped 10% to an all-time high of ₹389 after Q2 FY27 net profit surged 133% to ₹56.22 crore and revenue rose 122% to ₹187.86 crore. Management also raised FY27 guidance to ₹880 crore revenue and ₹275 crore net profit.
Q2: Did the stock rise on November 13?
No. Cupid shares fell over 5% at the open on November 13 after hitting a fresh record high of ₹393, as investors booked profits following the previous day’s surge.
Q3: What does Cupid Ltd actually do now?
Cupid manufactures male and female condoms, lubricants, and consumer healthcare products. Its business has shifted significantly: 67% of H1 FY27 revenue came from domestic consumer healthcare and FMCG, while 33% came from international B2B exports and institutional tenders.
Q4: What is Cupid’s FY27 guidance?
The company expects revenue of at least ₹880 crore and net profit of ₹275 crore or more for FY27, significantly higher than its previous guidance.
Q5: Is Cupid a good investment now?
The business is growing rapidly, but the stock has already rallied over 250% year-to-date. The risk-reward is less favourable after such a sharp run-up. Investors should consider entry points carefully and size positions appropriately for a volatile small-cap.
